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Background: Optimal adherence to antiretroviral therapy (ART) is necessary for people living with HIV/AIDS (PLHIV).
There have been relatively few systematic analyses of factors that promote or inhibit adherence to antiretroviral
therapy among PLHIV in Asia. This study assessed ART adherence and examined factors associated with suboptimal
adherence in northern Viet Nam.
Methods: Data from 615 PLHIV on ART in two urban and three rural outpatient clinics were collected by medical
record extraction and from patient interviews using audio computer-assisted self-interview (ACASI).
Results: The prevalence of suboptimal adherence was estimated to be 24.9% via a visual analogue scale (VAS) of
past-month dose-missing and 29.1% using a modified Adult AIDS Clinical Trial Group scale for on-time dose-taking
in the past 4 days. Factors significantly associated with the more conservative VAS score were: depression (p <
0.001), side-effect experiences (p < 0.001), heavy alcohol use (p = 0.001), chance health locus of control (p = 0.003),
low perceived quality of information from care providers (p = 0.04) and low social connectedness (p = 0.03). Illicit
drug use alone was not significantly associated with suboptimal adherence, but interacted with heavy alcohol use
to reduce adherence (p < 0.001).
Conclusions: This is the largest survey of ART adherence yet reported from Asia and the first in a developing
country to use the ACASI method in this context. The evidence strongly indicates that ART services in Viet Nam
should include screening and treatment for depression, linkage with alcohol and/or drug dependence treatment,
and counselling to address the belief that chance or luck determines health outcomes.
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Most studies examining the prevalence and determinants
of antiretroviral therapy (ART) adherence have been
conducted in the United States, Europe and Africa, but
relatively few have been performed in Asia [1]. We have
identified only 16 published articles on ART adherence in
Asia from 2002–2011. In general, the estimates from Asia
indicate that ART adherence is substantially higher than
adherence in the United States and Europe, and somewhat
higher than adherence in Africa. In Asia, these studies* Correspondence: dmh@hsph.edu.vn
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reproduction in any medium, provided the orreported that suboptimal adherence in the week or month
preceding interview was 0.4%–26%, with most studies
reporting suboptimal adherence under 15%. High adher-
ence estimates in Asia may arise from adherence over-
reporting due to the common practice of face-to-face
interviewing in clinical environments, often where health
care providers are present or even conduct interviews
[2,3]. Recent studies in Viet Nam have highlighted these
problems and drawn attention to the need for a more con-
fidential approach to data collection [4].
In Viet Nam, the number of PLHIV receiving ART
rapidly expanded from 500 in 2004 to more than 49,000
in early 2011. To date, only two published studies in VietThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adherence. Jordan et al. recruited 100 current or former
injection drug users in Hanoi and found that 85% were
optimal adherers [5]. The second study followed a co-
hort of 248 PLHIV at two out-patient clinics in Ho Chi
Minh City and reported an adherence of over 98% [4].
Neither study in Viet Nam quantitatively examined de-
terminants of ART adherence.
In their systematic review, Simoni et al. recommended
that information on ART adherence be collected using a
method like the audio computer-assisted self-interview
(ACASI) [6]. ACASI is a computerized method for ad-
ministering questionnaires. It has been widely used in
health studies in both developed and developing coun-
tries, especially on sensitive topics such as HIV/AIDS,
other sexually transmitted diseases, and drug use [7-9].
Instead of providing answers directly to interviewers, the
respondents simultaneously read and listen to questions
via headphones and type their answers, without being
witnessed or overheard by others [7]. ACASI maximizes
patients’ anonymity, minimizes the influence of health
care providers in the data collection process and eases
patients’ concerns about the impact of the interview on
their treatment [6,9]. Thus, ACASI reduces social desir-
ability response bias compared with in-person interviews
[8,10]. In Viet Nam, this technique has been shown to
be acceptable in studies of sensitive health issues with
both adolescents and injection drug users [9,11].
In this study we assess the level of suboptimal adher-
ence to ART among PLHIV and examine the influence
of a range of possible determinants of ART adherence in
Northern Viet Nam, using the ACASI technique.
Methods
Study sites
The study was carried out in five outpatient clinics in two
provinces in northern Viet Nam. The sites included Dong
Da Hospital and Dong Anh District Health Center in Hanoi
City (urban area) and Hai Duong Provincial AIDS Center,
Kim Mon District Health Center and Chi Linh District
Health Center in Hai Duong Province (rural areas). These
five clinics provided ART services to 1005 HIV/AIDS pa-
tients. The two clinics in Hanoi received support from the
President’s Emergency Plan for AIDS Relief, and the three
clinics in Hai Duong received support from the Global
Fund for AIDS, Tuberculosis and Malaria.
Study participants
Patients were eligible for the study if they were aged 18 -
years or older and they had received ART for at least 3 -
months. Patients were excluded if they had any serious
health problems that impaired their ability to answer the
questionnaire by themselves, were unable to come to the
study sites, or refused to participate. The study used aclinic-based cross-sectional design. The sample size was
calculated using the WHO Sample Size Determination
for Health Studies formula [12]:
n ¼ Ζ
2
1α=2p 1 pð Þ
d2
The following parameters were used to calculate the
sample size: proportion of adherence (P) among HIV/
AIDS patients in Viet Nam, which has been estimated to
be about 85% [13], absolute precision (d) of 5% and a
confidence level (z21−α/2) of 95%. This gave a sample size
of 289. To increase the statistical power and to incorpor-
ate a design effect due to clustering within clinics, the
sample size was multiplied by two (N = 578). In anticipa-
tion of incomplete interviews we then increased the final
sample size by 5% (29 cases), yielding a minimum survey
sample of 607 people. The number of patients studied
per clinic was proportional to the number of eligible pa-
tients in each clinic. Eligible patients were contacted and
invited to participate in the study when they came to the
out-patient clinics to pick up their monthly medications.
Patients were recruited consecutively between December
2008 and March 2009 until the minimum sample size
was reached. This study was approved by the Research
Ethics Committees of the Hanoi School of Public Health
in Viet Nam and the Queensland University of Technol-
ogy in Australia.
Data collection
The survey instruments were field tested, and validated,
as previously described [14]. All interview questions re-
lated to ART adherence and potential determinants of
ART adherence were voice-recorded in the ACASI pro-
gram developed specifically for this study using Visual
Basic and Microsoft Access. A simple set of equipment,
comprising a computer with installed ACASI software, a
mouse, and headphones, was provided to all respon-
dents. Participants listened to questions via headphones
while simultaneously reading them on a computer moni-
tor, and entered responses directly into the computer
without verbalizing their answers.
The ACASI interviews were conducted in private
rooms, and respondents were told that their information
would be kept confidential. Data collection was performed
by researchers who were not involved in the provision of
care, and no health care providers were involved in the in-
terviews or handling the data. To complement data from
the ACASI interviews, some clinical information was
extracted through review of medical records, with patients’
informed consent. The ACASI technique proved to be
highly acceptable to patients, and most participants re-
quired only a few minutes to familiarize themselves with
the method. This technique also eliminated interviewer
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duct face to face interviews, and also prevented potential
data entry errors.
ART adherence measurement
The study used two measures of ART adherence through
self-report. First, a visual analogue scale (VAS) was
adopted from Walsh et al. [15]. Respondents were asked
to specify the percentage of ART doses taken in the past
month by indicating a position along a continuous line
between 0% and 100%.
Second, the Adult AIDS Clinical Trials Group (AACTG)
adherence baseline questionnaire was adapted with minor
modification, as a means to cross-validate the VAS adher-
ence estimate [16]. While the original AACTG question-
naire asks for the number of missing doses in the past
4 days, in the present study respondents were asked about
the number of doses they did not take on time in the past
4 days. The level of adherence was defined as the propor-
tion of prescribed pills actually taken on time (i.e., within
1 hour of scheduled dose time) over a 4-day period. We
used this time range because a previous study found that
the proportion of prescribed doses taken on time (i.e.,
[number of doses taken ±1 h of dose time]/[total number
of prescribed doses]) was found to be strongly associated
with viral suppression [17].
Both the VAS and the AACTG questionnaire were se-
lected for this study because they are the most commonly
used tools in ART adherence studies worldwide [6]. Both
are valid in a variety of clinical settings because they lead
to similar estimates of the relationship between adherence
and viral suppression [18-20]. An adherence of less than
95% was classified as non-adherent in this study. This
threshold was set because adherence of less than 95% is
associated with virologic failure and thus considered sub-
optimal [21].
Measurements of predictor variables
Variables potentially associated with ART adherence were
selected based on a global literature review [1] and find-
ings from a qualitative study previously conducted in Viet
Nam [14]. The first group of variables were individual fac-
tors: gender, age, education, occupation, marital status, al-
cohol use, illicit drug use, depression, chance health locus
of control (i.e., the degree to which individuals believe that
their health status is controlled by chance or luck), and
use of adherence reminder tools (e.g., clock or cell phone
alarm, cell phone message, television or radio program).
The second group of variables were clinical and health
system factors: ART regimen, duration on therapy, medi-
cation side-effect experiences, current tuberculosis (TB)
treatment, cotrimoxazole use, clinic location (urban or
rural), distance from home to clinic, provider-patient rela-
tionship, and patient satisfaction with providers. The thirdgroup of variables was those related to social support: level
of satisfaction with social support (by family, friends, peer
educators, and social organizations), social connectedness,
and perceptions of social isolation.
Substance use was categorized dichotomously. Heavy al-
cohol consumption was five or more 30-50-ml drinks of
strong alcohol drinks or five 330-ml bottles of beer within
a few hours at any time in the preceding month. Illicit
drug intake occurring on one or more occasions during
the preceding month was noted. The Center for Epidemi-
ologic Studies’ Depression Scale (CES-D) [22,23] was used
to measure depressive symptoms. Those with a score of
27 or higher were classified as having probable major de-
pression [24]. Internal consistency (Cronbach’s α) for the
CES-D was 0.89. Chance health locus of control was mea-
sured with a subscale of the multidimensional health locus
of control (MHLC) scale [25] (Cronbach’s α = 0.78). The
AACTG instrument was used to measure medication
side-effect experiences [26]. A patient reaction assessment
tool with three sub-scales on patients’ perception related
to health care providers was used to measure the
provider-patient relationship [27]. Cronbach’s α of per-
ceived quality of the information from providers, affective
behaviours, and perceived ability of providers to initiate
communication were 0.85, 0.83 and 0.90, respectively. A
four-point Likert scale was used to assess patients’ satisfac-
tion with their social support from various groups (i.e.,
family members, friends, peer educators, and social orga-
nizations). Last, a scale by Hawthorne [28] was used to
measure social connectedness (Cronbach’s α =0.70) and
social isolation (Cronbach’s α = 0.77).
The outcome variables and most predictor variables were
collected with the ACASI questionnaire. The following
clinical variables were extracted from patient medical re-
cords: ART regimen, name and number of each ARV drug
prescribed per dose, number of doses per day, duration on
therapy, current TB treatment, and cotrimoxazole use.
Data analysis
Data extracted from medical records were manually entered
and merged with the ACASI data file into a single dataset.
Microsoft Access (Microsoft Inc., Redmond, WA, USA)
and MySQL database (MySQL Inc., Seattle, Washington,
USA) were used for data entry and management. The Stat-
istical Package for the Social Sciences 17.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analysis.
Both measures of ART adherence (i.e., the VAS past-
month dose adherence and the AACTG 4-day time adher-
ence) were dichotomized into non-adherent and adherent.
Agreement between the two measures was tested using the
kappa (k) statistic. Univariate logistic regression analyses
were conducted to assess the association of all hypothe-
sized independent variables with the VAS past-month dose
adherence. Multivariate logistic regression analysis was
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optimal adherence at p ≤ 0.1 in the univariate analysis,
along with variables that were hypothesized a priori to be
strong predictors of ART adherence. Because significant
co-linearity was found between heavy alcohol use and illicit
drug use in the prior month, those variables were entered
in combination in the multivariate analysis. All hypotheses
were tested at the 95% probability level.
Results
Characteristics of study participants
Among 953 eligible patients, 759 were contacted in person,
among whom 622 provided informed consent. Data from
seven patients were excluded because of incomplete ques-
tionnaire response, resulting in 615 patients in the final
sample. The characteristics of participants are summarized
in Table 1. One third of participants were female and the
ages of participants ranged from 18–60 years. More thanTable 1 Characteristics of participants (N=615)
Socio-demographic and behavioral characteristics n
Sex (Female) 209 3
Age (Mean: 32.7± 6.2)
18–30 250 4
31–40 301 4
>=41 64 1
Education
<=Primary 57
Secondary 301 3
High school 199 3
College or University 115 1
Occupation
Unemployed 119 1
Salary-paid job 284 4
Others (farmer, labor works. . .) 212 3
Marital status
Single 114 1
Married or live w partners 354 5
Divorced/separated/widow 147 2
Alcohol use (last month) 321 5
Had >5 drinks (last month) 215 3
Illicit drug use (ever) 319 5
Illicit drug use (last month) 87 1
Use of adherence aid 491 7
Depression
No depressive symptoms 135 2
Mild depressive symptoms 334 5
Major depressive symptoms 146 2
1d4T, stavudine; 3TC, lamivudin; NVP, nevirapine; EFV, efavirenz, AZT, zidovudine.half of the participants reported that they had consumed
alcohol in the previous month, and of those 68.9% admit-
ted to heavy drinking (more than five drinks in 2 hours) at
least once during the month. About half had ever used
illicit drugs, while 11.9% reported using an illicit drug in
the prior month. When scores on the Depression scale
were categorised according to the classification of Zich
et al. [24], more than half of the patients had at least mild
depressive symptoms (score of 16–26) and almost one
fourth had major depressive symptoms (score of 27+).
Suboptimal ART adherence
The prevalence of one-month suboptimal adherence mea-
sured by VAS was 24.9% (153/615), while the prevalence
of 4-day not-on-time-adherence using the AACTG instru-
ment was 29% (179/615). The observed agreement of the
two measurements was 84%, with a kappa coefficient of
0.596 (standard error = 0.04, p < 0.001). This indicates that% Clinical characteristics n %
4.0% ART regimen 1
d4T + 3TC + NVP 356 57.9%
0.7% d4T + 3TC + EFV 165 26.8%
8.9% AZT + 3TC + NVP 52 8.5%
0.4% AZT + 3TC + EFV 17 2.8%
Others 25 4.1%
9.3% Duration of ART (months) (Mean: 20.2±13.2)
9.7% <=12 months 201 32.7%
2.4% 13–24 months 221 35.9%
8.7% >24 month 193 31.4%
Tuberculosis treatment
9.3% Ongoing 42 6.8%
6.2% In the past 115 18.7%
4.5% Never 458 74.5%
Cotrimoxazole prophylaxis use
8.5% Ongoing 195 31.7%
7.6% In the past 175 28.5%
3.9% Never 245 39.8%
2.2% Facility location
4.0% Rural 409 66.5
1.9% Urban 206 33.5
1.9% Administrative level of facility
9.8% Provincial/City level 353 57.4
District level 262 42.6
2.0% Distance from residence to clinic
4.3% <=10 km 302 49.1
3.7% >10 km 313 50.9
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ther as adherent or as non-adherent by the two measures,
while 16% had discordant classification (Table 2).
Factors associated with suboptimal ART adherence
Table 3 and 4 summarise the results of logistic regres-
sion analyses of factors associated with suboptimal ART
adherence measured by VAS, which is more conservative
than the AACTG results. Significant associations were
observed in the univariate analyses for heavy alcohol use
in the prior month, illicit drug use in the prior month,
shorter distance from residence to clinic (<10 km), de-
pressive symptoms, a greater number of medication side
effects, a high level of chance health locus of control, a
low perceived quality of information from health care
providers, low satisfaction with received support, and
low social connectedness. Socio-demographic character-
istics (i.e. gender, age, and education) were not associ-
ated with suboptimal adherence to ART.
In multivariate analysis, factors that remained signifi-
cantly associated with suboptimal adherence to ART
were depression, heavy alcohol use in the prior month,
medication side-effect experiences, chance health locus
of control, low perceived quality of information from
care providers, and low level of social connectedness. Al-
though illicit drug use in the prior month without heavy
alcohol use was not associated with suboptimal adher-
ence, a significant interaction was found between illicit
drug use and heavy alcohol use in the prior month. Par-
ticipants who reported only heavy alcohol use had an ad-
justed odd ratio (aOR) of 2.14 (CI: 1.34-3.41), while
those who reported both heavy alcohol use and illicit
drug use had an aOR of 5.04 (CI: 2.46-10.32).
Discussion
This study is based on a large and diverse sample of sub-
jects enrolled in ART programs in Viet Nam, and indi-
cates that suboptimal ART adherence is a critical issue
that requires attention. Using the VAS measurement, we
found that one in four (24.9%) people taking ART were
not optimally adherent over the preceding month, and a
higher proportion (29.1%) were classified as non-adherentTable 2 Agreement between two measures of ART adherence
VAS score2
Subopti
Suboptimal adherence
Optimal adherence
Total
Suboptimal adherence
Optimal adherence 62(10.1%)
Total 179(29.1%)
1 AACTG, Adult AIDS Clinical Trial Group; 2 VAS, Visual Analogue Scale.with the AACTG measure of 4-day on-time medication
use. These two prevalence estimates are higher than both
prior studies in Viet Nam [4,5]. Compared with other pub-
lished studies from East and South Asia, the suboptimal
adherence we report is at the high end of the range (from
0.4% to 26.0%).
Direct comparison of suboptimal ART adherence preva-
lence from various studies is hindered by differences in
study design and adherence measures, including time ref-
erence periods. Face-to-face interviews may be unreliable
because patients may not be honest about their subopti-
mal adherence when they are interviewed by clinic staff
about this sensitive issue. To our knowledge, the present
study is the first to use the ACASI technique to investigate
ART adherence in a developing country. This approach is
widely used in other contexts to reduce social desirability
response bias and enhance the veracity of self-report [6,9].
In Viet Nam, this technique has been useful to enhance
disclosure of sensitive information in analyses with adoles-
cents and injection drug users [9]. The improved privacy
and confidentiality of the ACASI method may explain the
relatively high estimates of suboptimal adherence we
report here.
This study extends previous analyses of the determinants
of ART suboptimal adherence that have been conducted in
Asia and other regions in the world, and has clear implica-
tions for care for PLHIV in low resource environments.
Among the many variables examined, depressive symptoms
had one of the strongest associations with suboptimal ad-
herence. This is consistent with research from high-income
countries and in Africa [29-33] and strengthens the argu-
ment for mental health services that may improve ART ad-
herence outcomes [33-36]. Currently, mental health
services are not available at most HIV outpatient clinics in
Viet Nam [4].
This study also confirmed that heavy alcohol use is a
significant predictor of suboptimal ART adherence. Glo-
bally, alcohol use has been recognized as a major barrier
for medication adherence [37]. A meta-analysis reported
that among PLHIV, those who drink alcohol were ap-
proximately 40–50% less likely to be adherent compared
with those who abstain or drink relatively little, and the(N=615)
AACTG score1
mal adherence Optimal adherence Total
117(19.0%) 36(5.9%) 153(24.9%)
62(10.1%) 400(65.0%) 462(75.1%)
179(29.1%) 436(70. 9%) 615(100%)
117(19.0%) 36(5.9%) 153(24.9%)
400(65.0%) 462(75.1%)
436(70. 9%) 615(100%)
Table 3 Factors associated with suboptimal ART adherence measured by the visual analogue scale (N=615)
Factors % of optimal adherentgroup (n=462)
% of suboptimal adherent
group (n=153)
Unadjusted OR1
(95% CI)
Adjusted OR2
(95% CI) P value
3
Socio-demographic factors
Sex Male 74.0 26.0 1
Female 78.0 22.0 0.79(0.53–1.20) – –
Age 18–30 74.8 25.2 1 – –
31–40 74.8 25.2 1.00(0.68–1.48)
>= 40 78.1 21.9 0.83(0.43–1.61)
Education <= Primary 59.6 40.4 1
Higher 72.0 28.0 0.58(0.33–1.03) – –
Clinical factors
Site
Kinh Mon &
Chi Linh
67.9 32.1 1 1
Dong Da 72.9 27.1 0.79(0.41–1.49) 1.20(0.57–2.52) 0.628
Dong Anh 82.0 18.0 0.46(0.24–0.90) 0.59(0.27–1.29) 0.188
Hai Duong 71.3 28.7 0.85(0.44–1.65) 1.34(0.61–2.93) 0.464
Distance from residence
to clinic
>10 km 78.6 21.4 0.68(0.47–0.99) 0.83(0.53–1.28) 0.396–
Alcohol and drug use
Heavy alcohol use
(last month)
No 81.6 18.4 1 – –
Yes 69.2 30.8 1.98(1.36–2.89)
Illicit drug Use
(last month)
No 77.7 22.3 1 – –
Yes 56.2 43.8 2.72(1.64–4.50)
Interaction between drug
and alcohol use
No drug +
No alcohol
81.2 18.8 1 1
No drug +
Alcohol
69.5 30.5
1.90(1.25–2.89) 2.14(1.34–3.41) .001
Drug +
No alcohol
71.4 28.6
1.73(0.73–4.09) 1.49(0.59–3.80) .402
Drug + Alcohol 46.7 53.3 4.94(2.61–9.37) 5.04(2.46–10.32) <0.001
Depression No/mild
symptom
78.7 21.3 1 1
Major
symptom
63.7 36.3 2.10(1.40–3.14) 3.26(2.04–5.22) <0.001
1 unadjusted odds ratio of suboptimal adherence is obtained from the univariate analysis; 2 adjusted odds ratio is obtained from multivariate analysis
(95% confidence interval); 3 p values of the adjusted odds ratio.
Table 4 Continuous factors
Factors
Mean of optimal adherent
group (n=462)
Mean of suboptimal adherent
group (n=153)
Unadjusted OR1
(95% CI)
Adjusted OR2
(95% CI) P value
3
Side-effects experienced 20.64 27.19 1.02(1.01–1.04) 1.03(1.01–1.04) <0.001
Chance health locus of control 16.6 18.69 1.06(1.02–1.09) 1.06(1.02–1.09) 0.001
Social related factors
Perceived quality of information
from HCPs
23.32 22.16 0.91(0.86–0.95) 0.93(0.88–0.99) 0.021
Satisfaction with received support 8.49 7.73 0.88(0.82–0.95) 0.94(0.86–1.02) 0.138
Social connectedness 10.89 9.65 0.90(0.86–0.95) 0.94(0.88–0.99) 0.033
1 unadjusted odds ratio of suboptimal adherence is obtained from the univariate analysis; 2 adjusted odds ratio is obtained from multivariate analysis (95%
confidence interval); 3 p values of the adjusted odds ratio.
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present study found that recent illicit drug use was not it-
self associated with suboptimal ART adherence, but we
identified a significant interaction with recent heavy alcohol
use. Compared with subjects with recent heavy alcohol use
alone, ART adherence was much poorer among subjects
who reported heavy alcohol use and illicit drug use. A num-
ber of interventions currently exist in Viet Nam to support
drug users, including methadone maintenance therapy,
needle and syringe exchange, condom distribution, and
peer support groups. However, little effort has been di-
rected to support alcohol abusers, including alcohol abusers
living with HIV/AIDS. An important implication of our
findings is that care and support for people who use alcohol
and/or illicit drugs should be enhanced and sustained in
Viet Nam, as a core part of comprehensive efforts to im-
prove HIV treatment adherence. These efforts should be
conducted in parallel with research, because few systematic
evaluations have assessed the effectiveness of programs
designed to optimize ART adherence for substance users,
especially in resource-limited settings [38].
Another psychological factor identified was the fatalistic
belief that chance or luck controls one’s destiny, including
health outcomes. The multivariate results indicated that
after adjusting for other variables, chance health locus of
control remained a significant predictor of suboptimal
ART adherence. This finding may be used to guide HIV
clinic counsellors to discuss fatalistic beliefs as a barrier to
self-care and healthy behaviours. Consistent with other re-
search of the influence of patient-provider relationships
on ART adherence [39,40], this study found that the per-
ceived quality of information from health care providers
was positively associated with adherence.
An interesting insight emerged from the analysis of how
family and social support influence adherence. With a
relatively large sample size, this study had enough statis-
tical power to examine the relative importance of different
types of social and family support in a multivariable
model. We did not find significant relationships between
ART adherence and different types of support from family,
peers and social organisations. Both patient overall satis-
faction with support received, and feelings of social con-
nectedness, significantly correlated with adherence. In
developing countries, a sense of social responsibility may
influence patient adherence [41]. Specific interventions to
enhance a sense of connectedness that maintains and
strengthens social responsibility among patients, their
families, and peers may help to optimize ART adherence.
The present study has some limitations. Selection bias
may have occurred, because only patients on ART treat-
ment who came to a clinic at the time of data collection
and provided informed consent were included. This ex-
cluded patients who were not retained in HIV care, pa-
tients who missed clinical appointments during the studyperiod, or patients who refused to participate in the study.
Although the number of patients studied per clinic was
proportional to the number of patients registered and re-
ceiving ART in each site, and researchers made consider-
able efforts to revisit these clinics several times to recruit
patients, it is conceivable the non-participants were at
higher risk of poor adherence. Therefore, the current study
may underestimate the true level of suboptimal ART adher-
ence. A further limitation is the cross-sectional nature of
this study, which limits the ability of the analysis to deter-
mine the direction of causation.Conclusions
We report here the largest study of ART adherence
among PLHIV in South East Asia. The participants were
a diverse group from five clinics located in both rural and
urban areas. The level of suboptimal adherence to ART ap-
pears to be higher than estimated in previous Asian studies.
This may be due to the interview mode of the current study
(ACASI) which enhances privacy and confidentiality and
may improve the validity of self-reported information. Sub-
optimal adherence was strongly influenced by depression,
ongoing substance use, medication side effects, and poor
social connectedness. The study findings can be used to
optimize ARV treatment adherence in Viet Nam.
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